Alemtuzumab for the treatment of relapsing-remitting multiple sclerosis

ERG additional analyses 2

Produced by Southampton Health Technology Assessments Centre (SHTAC)

Authors Emma Loveman

Jeremy Jones

Jackie Bryant

Keith Cooper

Correspondence to Emma Loveman

Senior Research Fellow

Southampton Health Technology Assessments Centre (SHTAC)

University of Southampton

First Floor, Epsilon House

Enterprise Road, Southampton Science Park

Southampton SO16 7NS

Date completed 20/02/2014

Following the appraisal committee meeting SHTAC were requested to undertake an additional exploratory analysis.

Analyses were conducted using the manufacturer's combination model 7, with waning of 50% after five years. Analyses use 3 month SAD for disease progression for alemtuzumab vs. fingolimod and 6 month SAD for disease progression for alemtuzumab vs. natalizumab, and post-2000 MTC as per the manufacturer's analysis. The GMS assumed price of the PAS for fingolimod (£13,000) was also used. Results can be seen in Table 1 and Table 2 respectively.

Alemtuzumab vs. fingolimod for HA RRMS

Table 1: Results for almetuzumab vs fingolimod for HA RRMS with changes to hazard ratios

	Alemtuzumab		Fingolimod		Incremental		ICER (£ per QALY gained)
	Costs (£)	QALYS	Costs (£)	QALYs	Costs (£)	QALYs	
Base case	£258,644	8.92	£257,257	7.02	£1,387	1.90	£731
HR Alemtuzumab	£258,644	8.92	£252,448	7.53	£6,196	1.39	£4,460
HR Fingolimod	£271,905	8.01	£257,257	7.02	£14,648	0.99	£14,788
HR half way between each	£265,379	8.45	£254,842	7.27	£10,537	1.18	£8,942

Alemtuzumab vs. natalizumab for RES RRMS

Table 2: Results for almemtuzumab vs natalizumab for RES RRMS with changes to hazard ratios

	Alemtuzumab		Natalizumab		Incremental		ICER (£ per QALY gained)
	Costs (£)	QALYS	Costs (£)	QALYs	Costs (£)	QALYs	
Base case	£245,755	9.77	£316,727	8.14	-£70,972	1.63	Dominates
HR Alemtuzumab	£245,755	9.77	£315,831	8.38	-£70,075	1.39	Dominates
HR Natalizumab	£251,324	9.39	£316,727	8.14	-£65,403	1.26	Dominates
HR half way between each	£248,512	9.58	£316,253	8.26	-£67,742	1.32	Dominates